These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18064402)

  • 1. The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA.
    Schüller A; Suhartono M; Fechner U; Tanrikulu Y; Breitung S; Scheffer U; Göbel MW; Schneider G
    J Comput Aided Mol Des; 2008 Feb; 22(2):59-68. PubMed ID: 18064402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots".
    Davis B; Afshar M; Varani G; Murchie AI; Karn J; Lentzen G; Drysdale M; Bower J; Potter AJ; Starkey ID; Swarbrick T; Aboul-ela F
    J Mol Biol; 2004 Feb; 336(2):343-56. PubMed ID: 14757049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaffold-hopping potential of fragment-based de novo design: the chances and limits of variation.
    Krueger BA; Dietrich A; Baringhaus KH; Schneider G
    Comb Chem High Throughput Screen; 2009 May; 12(4):383-96. PubMed ID: 19442066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.
    Renner S; Ludwig V; Boden O; Scheffer U; Göbel M; Schneider G
    Chembiochem; 2005 Jun; 6(6):1119-25. PubMed ID: 15883975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening.
    Du Z; Lind KE; James TL
    Chem Biol; 2002 Jun; 9(6):707-12. PubMed ID: 12079782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks.
    Schneider G; Lee ML; Stahl M; Schneider P
    J Comput Aided Mol Des; 2000 Jul; 14(5):487-94. PubMed ID: 10896320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing interaction of a fluorescent ligand with HIV TAR RNA.
    Qi L; Zhang J; He T; Huo Y; Zhang ZQ
    Spectrochim Acta A Mol Biomol Spectrosc; 2017 Feb; 173():93-98. PubMed ID: 27611591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA.
    Lind KE; Du Z; Fujinaga K; Peterlin BM; James TL
    Chem Biol; 2002 Feb; 9(2):185-93. PubMed ID: 11880033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR.
    Filikov AV; Mohan V; Vickers TA; Griffey RH; Cook PD; Abagyan RA; James TL
    J Comput Aided Mol Des; 2000 Aug; 14(6):593-610. PubMed ID: 10921774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flux (1): a virtual synthesis scheme for fragment-based de novo design.
    Fechner U; Schneider G
    J Chem Inf Model; 2006; 46(2):699-707. PubMed ID: 16563000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR.
    Zeiger M; Stark S; Kalden E; Ackermann B; Ferner J; Scheffer U; Shoja-Bazargani F; Erdel V; Schwalbe H; Göbel MW
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5576-5580. PubMed ID: 25466178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling of HIV-1 TAR RNA-ligand complexes.
    Mitrasinovic PM; Tomar JS; Nair MS; Barthwal R
    Med Chem; 2011 Jul; 7(4):301-8. PubMed ID: 21574948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design.
    Fechner U; Schneider G
    J Chem Inf Model; 2007; 47(2):656-67. PubMed ID: 17315990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concept of combinatorial de novo design of drug-like molecules by particle swarm optimization.
    Hartenfeller M; Proschak E; Schüller A; Schneider G
    Chem Biol Drug Des; 2008 Jul; 72(1):16-26. PubMed ID: 18564216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA.
    Long KS; Crothers DM
    Biochemistry; 1995 Jul; 34(27):8885-95. PubMed ID: 7612630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery.
    Chavali SS; Bonn-Breach R; Wedekind JE
    J Biol Chem; 2019 Jun; 294(24):9326-9341. PubMed ID: 31080171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence correlation spectroscopy at single molecule level on the Tat-TAR complex and its inhibitors.
    Nandi CK; Parui PP; Brutschy B; Scheffer U; Göbel M
    Biopolymers; 2008 Jan; 89(1):17-25. PubMed ID: 17764074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 TAR RNA enhances the interaction between Tat and cyclin T1.
    Zhang J; Tamilarasu N; Hwang S; Garber ME; Huq I; Jones KA; Rana TM
    J Biol Chem; 2000 Nov; 275(44):34314-9. PubMed ID: 10944537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOGS: reaction-driven de novo design of bioactive compounds.
    Hartenfeller M; Zettl H; Walter M; Rupp M; Reisen F; Proschak E; Weggen S; Stark H; Schneider G
    PLoS Comput Biol; 2012; 8(2):e1002380. PubMed ID: 22359493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of a cyclic BIV beta-Tat peptide with its TAR RNA construct.
    Tok JB; Des Jean RC; Fenker J
    Bioorg Med Chem Lett; 2001 Jan; 11(1):43-6. PubMed ID: 11140729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.